| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 256.500 +20.47% on 03/26/24 | | 310.000 -0.32% on 04/25/24 | +42.000 (+15.73%) since 03/25/24 |
| 3-Month | 190.400 +62.29% on 02/05/24 | | 310.000 -0.32% on 04/25/24 | +91.500 (+42.07%) since 01/25/24 |
| 52-Week | 173.600 +78.00% on 06/23/23 | | 338.000 -8.58% on 10/30/23 | +63.000 (+25.61%) since 04/25/23 |
SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today...
HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter...
— 49% ORR amongst SAVANNAH patients with higher MET levels —...
SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
| 3rd Resistance Point | 308.313 |
| 2nd Resistance Point | 305.657 |
| 1st Resistance Point | 300.828 |
| Last Price | 306.000 |
| 1st Support Level | 293.343 |
| 2nd Support Level | 290.687 |
| 3rd Support Level | 285.858 |
| 52-Week High | 338.000 |
| Last Price | 306.000 |
| Fibonacci 61.8% | 275.199 |
| Fibonacci 50% | 255.800 |
| Fibonacci 38.2% | 236.401 |
| 52-Week Low | 173.600 |